Insight into the profibrinolytic activity of dermatan sulfate: Effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators

Thrombosis Research

Volumn 120, Issue 5, 2007, Pages 745-752

  Castañon, María Mercedes ^a   Gamba, Cecilia ^a   Kordich, Lucía C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Dermatan sulfate; Fibrin fibrinogen degradation products; Plasminogen activation; Tissue plasminogen activator; Urinary plasminogen activator

Indexed keywords

DERMATAN SULFATE; FIBRIN DEGRADATION PRODUCT; GLUTAMIC ACID; HEPARIN COFACTOR II; PLASMIN; PLASMINOGEN; PLASMINOGEN[GLUTAMIC ACID]; PLASMINOGEN[LYSINE]; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; MOLECULAR WEIGHT; PLASMINOGEN ACTIVATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REACTION ANALYSIS;

ANTICOAGULANTS; ANTITHROMBINS; DERMATAN SULFATE; FIBRINOLYSIS; GLUTAMIC ACID; HUMANS; HYDROLYSIS; MODELS, CHEMICAL; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATORS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 34547942106     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.014     Document Type: Article

References (49)

1. Bachmann F. Plasminogen-plasmin enzyme system. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and Thrombosis. Basic Principles and clinical practice (2001), Lippincott Williams & Wilkins, Philadelphia, LA, USA 275-320
2. Holvoet P., Lijnen H.R., and Collen D. A monoclonal antibody specific for Lys-plasminogen. J Biol Chem 260 22 (1985) 12106-12111
3. Casu B. Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17 1 (1991) 9-14
4. Andrew M.A., Mitchell L., Berry L., Paes B., Delorme M., Ofosu F., et al. An anticoagulant dermatan sulfate proteoglycan circulates in pregnant woman and her fetus. J Clin Invest 89 1 (1992) 321-326
5. Delorme M.A., Saees N., Sevick A., Mitchell L., Berry L., Johnston M., et al. Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82 (1993) 3380-3385
6. Rossi E., Duboscq C., Peragallo M., and Kordich L. Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost (1997) 435 Suppl
7. Duboscq C., Rossi E., Quintana I., and Kordich L. Actividad del cofactor II de la heparina y concentración de dermatán sulfato en pacientes sépticos. Medicina 54 5/2 (1994) 509
8. Tollefsen D.M., Pestka C.A., and Monafo W.J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258 11 (1983) 6713-6716
9. Han J.H., Cote H.C.F., and Tollefsen D.M. Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272 (1997) 28660-28665
10. Bock S.C. Antithrombin III and heparin cofactor II. In: Colman R.W., Clowes A.W., Goldhaber S.Z., Marder V.J., and George J.N. (Eds). Hemostasis and Thrombosis. Basis Principles and Clinical Practice (2006), Lippincott Williams & Wilkins, Philadelphia-United States 235-248
11. Barbanti M., Calani F., Babbini M., Bergonzini G., Parma B., and Marchi E. Antithrombotic activity of Desmin 370 comparison with a high molecular weight dermatan sulphate. Thromb Res 71 (1993) 417-422
12. Agnelli G., Cosmi B., Di Filippo P., Ranucci V., Veschi F., Longetti M., et al. A randomized, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 67 (1992) 203-208
13. Prandoni P., Meduri F., Cuppini S., Toniato A., Zangrandi Z., Polisterna P., et al. Dermatan sulphate: a safe approach to prevention of post operative deep vein thrombosis. Br J Surg 79 (1992) 505-509
14. Kretz J., Chakje N., Wiesel M.L., Grunebaum L., Zamboni V., Palazzini E., et al. The treatment of deep vein thrombosis with intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study. Thromb Res 84 6 (1996) 391-398
15. Von Kemp K., Jochmans K., Tussenbroek F., Debruyne H., and Van den Brade P. Desmin (a low molecular weight dermatan sulfate) versus heparin in treatment of patients with deep venous thrombosis. Eur J Clin Pharmacol 54 2 (1998) 133-139
16. Attanasio E., Russo P., Carunchio G., and Caprino L. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19 1 (2001) 57-68
17. Taliani M.R., Agnelli G., Nenci G.G., and Gianese F. Dermatan sulfate in patients with heparin-induced thrombocytopenia. Br J Haematol 104 (1999) 87-89
18. Imberti D., Verso M., Silvestrini E., Taliani M.R., and Agnelli G. Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1 (2003) 2696-2697
19. Boccardo P., Melacini D., Rota S., Mecca G., Boletta A., Casiraghi F., et al. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Nephrol Dial Transplant 12 11 (1997) 2349-2354
20. Ryan K.E., Lane D.A., Flynn A., Ireland H., Boisclair M., Shepperd J., et al. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 68 5 (1992) 563-569
21. Van Ryn-McKenna J., Weber E.G.E., Ofosu F.A., and Buchnan M.R. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 61 1 (1989) 7-9
22. Van Ryn-McKenna J., Ofosu F.A., Gray E., Hirsh J., and Buchanan M.R. Effects of dermatan sulphate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 556 (1989) 304-312
23. Carrie D., Caranobe C., Gabaig A.M., Larroche M., and Boneu B. Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68 6 (1992) 637-641
24. Santoro F.M., Alvarez R., and Fussi F. Pharmacological profile of a native dermatan sulphate. Thromb Res 67 2 (1992) 201-211
25. Barbanti M., Calanni F., Milani M.R., Marchi E., Semerano N., and Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant-independent mechanism. Thromb Haemost 69 2 (1993) 147-151
26. Colucci M., Sardella L., Barbanti M., Calanni F., and Semerano N. Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats. Thromb Res 87 5 (1997) 441-446
27. Colucci M., Rossiello M.R., Barbanti M., Calanni F., and Semerano N. Prevention and therapy of experimental venous trombosis in rabbits by Desmin 370. Thromb Haemost 80 (1998) 338-341
28. Barbanti M., Calanni F., Marchi E., Semerano N., and Colucci M. Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of performed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost 73 2 (1995) 287-290
29. Tripodi A., Moia M., Bottasso B., Tenconi P.M., Gianese F., and Mannucci P.M. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 62 6 (1991) 663-672
30. Dettori A.G., Galli G., Manotti C., and Palazzini E. Pharmacological activity of a low molecular weight dermatan sulfate (Desmin) in healthy volunteers. Semin Thromb Hemost 20 3 (1994) 259-265
31. Harenberg J., Jeschek M., Acker M., Malsch R., Huhle G., and Heene D.L. Effect of low-molecular-weight dermatan sulphate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Blood Coagul Fibrinolysis 7 1 (1996) 49-56
32. Abbadini M., Zhu G.J., Maggi A., Pangrazzi J., Donati M.B., and Mussoni L. Dermatan sulphate induces plasminogen activator release in perfused rat hindquarters. Blood 70 6 (1987) 1858-1860
33. Krupinski K., Bielawiec M., Yoshida K., Kyogashima M., Takada Y., and Takada A. Dermatan sulphate enhances lysis of laser induced thrombus in vivo. Thromb Res 91 (1998) 199-202
34. Marsh N.A., Minter A.J., and Chesterman C.N. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 1 2 (1990) 133-138
35. Kyogashima M., Onaya J., Miyauchi S., Arai M., Shibata Y., Suda A., et al. Antithrombotic activity of avian crown dermatan sulphate. Thromb Res 96 (1999) 459-465
36. Paques E.P., Stohr H.A., and Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thromb Res 42 (1986) 797-807
37. Takada Y., Urano T., and Takada A. Effects of heparan sulfated analogue or other sulphate polysaccharides on the activation of plasminogen by t-PA and u-PA. Thromb Res 73 5 (1994) 301-311
38. Andrade-Gordon P., and Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 25 (1986) 4033-4040
39. Stein P.L., Van Zonneveld A.J., Pannekoek H., and Strickland S. Structural domains of human-type plasminogen activator that confer stimulation by heparin. J Biol Chem 264 26 (1989) 15441-15444
40. Stephens R.W., Bokman A.M., Myohanen H.T., Reisberg T., Tapiovaara H., Pedersen N., et al. Heparin binding to the urokinase kringle domain. Biochemistry 31 (1992) 7572-7579
41. Liang J.F., Li Y., and Yang V. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation. Thromb Res 97 (2000) 349-358
42. Takada A., Takada Y., and Sugawara Y. Effects of fibrinogen and fibrin on the activation of Glu- and Lys-Plasminogen by urokinase. Thromb Res 33 (1984) 561-569
43. Laemmli K.V. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
44. Rydzewski A., Takada Y., and Takada A. Stimulation of plasmin catalyzed conversion of single-chain to two chain urokinase-type plasminogen activator by sulphated polysaccharides. Thromb Haemost 62 2 (1989) 752-755
45. Dosne A.M., Bendetowitz A.V., Kher A., and Samama M. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and low molecular weight heparin. Thromb Res 51 (1988) 627-630
46. Mangel W.F., Lin B.H., and Ramakrishanan V. Characterization of an extremely large, ligand-induced conformational change in plasminogen. Science 248 4951 (1990) 69-73
47. Markus G., Evers J.L., and Hobika G.H. Comparison of some properties of native (Glu) and modified (Lys) human plasminogen. J Biol Chem 253 3 (1978) 733-739
48. Andrade-Gordon P., and Strickland S. Anticoagulant low molecular weight heparin does not enhance the activation of plasminogen by t-PA. J Biol Chem 264 26 (1989) 15177-15181
49. Edelberg J.M., Weissler M., and Pizzo S.V. Heparin oligosaccharides enhance t-PA: a correlation between oligosaccharide length and stimulation of plasminogen activation. Biochemistry 30 (1991) 10999-11003